Short answer
Atrium Therapeutics, Inc. (RNA) filed an 8-K current report with the SEC on October 9, 2026 reporting Item 8.01 (Other Events). Proposed PIPE issuance: 5,170,384 common shares plus pre-funded warrants for 1,134,930 shares.
Atrium Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Proposed PIPE issuance: 5,170,384 common shares plus pre-funded warrants for 1,134,930 shares
- Post-offering share count expected at 21,571,507, indicating material potential dilution
- Offering remains subject to closing conditions, creating execution and timing risk
- Shares include settlement of make-whole equity awards from the Avidity Biosciences spin-off
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Atrium Therapeutics, Inc. 8-K filings
Get the next RNA 8-K as it lands
Follow RNA for push alerts, or ask the research agent what this filing means.